TP53 and prostate adenocarcinoma: The mechanism consists of p21WAF1/CIP1 elevation via the inhibition of Mdm2, but only in the LNCaP (human prostate adenocarcinoma) cell line and not in MCF-7, despite elevated levels of p53 and p27Kip1 [81,82].